Provided is a fast-dispersing dosage form for oral delivery, wherein the fast-dispersing dosage form includes a rimegepant. Also provided is a method for delivering rimegepant to a subject, wherein the method includes orally administering to the subject a fast-dispersing dosage form including rimegepant.

An improved customizable dosage form comprising a substrate, such as a tablet core, that has one or more distinct, discreet cavities on its exterior surface, wherein simethicone is deposited into at least one of the cavities.

An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably where the metabolic disorder is one or more selected from the group consisting of ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or where the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

An inkjet ink which can sufficiently suppress photofading of printed images and has good lightfastness, and to provide a tablet including a printed part that is printed using the inkjet ink. The inkjet ink contains Blue No. 1 as a food dye, a disaccharide whose solubility in 100 ml of water at 20° C. is in the range of 20 g or more and 39 g or less as a fixing agent, and a solvent containing water and at least one of propylene glycol and ethanol.

An edible inkjet ink which can sufficiently suppress photodiscoloration or photofading of printed images and has good lightfastness, and to provide a tablet including a printed part that is printed using the edible inkjet ink. The edible inkjet ink contains Red No. 3, and hydroxy acid salt having two or more carboxyl groups.

Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.

A method for delivery of personalized medication or nutrition for an individual is provided. The method includes receiving parameters for the personalized medication at a 3D printer, wherein the parameters comprise one or more ingredients, mixing at least one of the ingredients at the 3D printer, and micro-dispensing the one or more of the ingredients into dose form at the 3D printer.

Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanparticles, and polymeric microparticles or nanparticles have been presented in the present invention. Compositions containing carvedilol encapsulated in liposomes showed higher bioavailability and lower clearance rate than that of the free solution after intravenous administration. In vitro release of those liposomes in buffer solutions shows drug extended release over 48 hours, and correspondingly the in vivo animal data shows that parenteral administration of carvedilol encapsulated in liposomal materials has sustained release PK profile.